ArticleCell systems2024
Integrating multiplexed imaging and multiscale modeling identifies tumor phenotype conversion as a critical component of therapeutic T cell efficacy.
Article in Cell systems, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- Iterative multiplex imaging cytometry for cross-species analyses of in situ tissue leukocytes.Journal of immunological methods · 2026Article
- Topologically-based parameter inference for agent-based model selection from spatiotemporal cellular data.PLoS computational biology · 2026Article
- Single-cell multiomics identifies an ALDH9A1-carnitine signaling axis driving resistance of NSCLC to immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Decoding cellular population dynamics through mechanistic modelling and statistical data analysis.NPJ systems biology and applications · 2026Review
- Tumor-immune trajectory context connects static tissue architecture to clinical outcomes.bioRxiv : the preprint server for biology · 2026Article
- Who's afraid of synthetic data? Hybrid approaches to deliver medical digital twins.Informatics in medicine unlocked · 2026Article
- Agent-based modeling of cellular dynamics in adoptive cell therapy.Communications biology · 2026Article
- Role of the neurotransmitter-receptor pathway in T-cell tumor immunology and cancer immunotherapy.Acta biochimica et biophysica Sinica · 2026Review
- A Roadmap for the Future of Systems Biology in Cancer Research.Cancer research · 2025Review
- T cell-macrophage crosstalk in GVHD and cancer immunotherapy.Cell investigation · 2025Article
- Fluid-Squid: DIY Multiplexed Imaging of Cells and Tissues.bioRxiv : the preprint server for biology · 2025Article
- Acquired resistance in cancer: towards targeted therapeutic strategies.Nature reviews. Cancer · 2025Review
- A Spatial Multi-Omic Framework Identifies Gliomas Permissive to TIL Expansion.Research square · 2025Article
- Immune and non-immune cell fencing of tumor cells is a widespread and functionally relevant spatial pattern in solid cancers.Computational and structural biotechnology journal · 2025Article
- Roles of immunosuppressive myeloid states in colorectal cancer checkpoint inhibitor non-response: single-cell and spatial proteomics, and reprogramming approaches.Frontiers in immunology · 2025Review
- Infiltration characteristics and regulatory mechanisms of CD8Frontiers in immunology · 2025Review
- Foundations of a Compositional Systems Biology.ArXiv · 2024Article
- FromFrontiers in molecular biosciences · 2024Article
- T cell-mediated curation and restructuring of tumor tissue coordinates an effective immune response.Cell reports · 2023Article
Corrections and comments
- Update of
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Cancer progression is a complex process involving interactions that unfold across molecular, cellular, and tissue scales. These multiscale interactions have been difficult to measure and to simulate. Here, we integrated CODEX multiplexed tissue imaging with multiscale modeling software to model key action points that influence the outcome of T cell therapies with cancer. The initial phenotype of therapeutic T cells influences the ability of T cells to convert tumor cells to an inflammatory, anti-proliferative phenotype. This T cell phenotype could be preserved by structural reprogramming to facilitate continual tumor phenotype conversion and killing. One takeaway is that controlling the rate of cancer phenotype conversion is critical for control of tumor growth. The results suggest new design criteria and patient selection metrics for T cell therapies, call for a rethinking of T cell therapeutic implementation, and provide a foundation for synergistically integrating multiplexed imaging data with multiscale modeling of the cancer-immune interface. A record of this paper's transparent peer review process is included in the supplemental information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.